Ex­clu­sive: Af­ter Turn­ing Point suc­cess, on­col­o­gy vets in-li­cense first as­set for Aven­zo Ther­a­peu­tics

Athena Coun­tou­ri­o­tis and her for­mer col­leagues at Turn­ing Point Ther­a­peu­tics have in-li­censed their first on­col­o­gy as­set at their next ven­ture, Aven­zo Ther­a­peu­tics, which is on the hunt for more deals and fi­nanc­ing lat­er this year, she told End­points News.

The San Diego start­up, which has raised about $200 mil­lion so far, in-li­censed a Phase I-stage CDK2 in­hibitor from Al­lo­ri­on Ther­a­peu­tics, a US and Chi­na biotech that an­nounced a sep­a­rate deal ear­li­er this week with As­traZeneca.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER